CUTANEOUS MELANOMA

This study tests a new oral drug, LNS8801, alone or combined with the immunotherapy pembrolizumab, in people with advanced melanoma that has stopped responding to prior treatments. About 135 participants will be randomly assigned to one of three groups: LNS8801 alone, LNS8801 plu…

This early-stage study tests a new medicine, PF-08046033, in adults with advanced lung, esophageal, or skin cancer that has spread or can't be removed. The main goal is to check safety and find the right dose. Participants receive the drug in cycles and are closely watched for si…

This study is for people with high-risk melanoma who have had surgery to remove their cancer. It uses a blood test to find tiny bits of tumor DNA that might be left behind. Participants will receive either a standard immunotherapy or a combination of two immunotherapy drugs to se…

This study tests new combinations of immunotherapy drugs given before surgery for people with advanced melanoma that is hard to treat. The goal is to see if these combinations can shrink or eliminate the tumor before it is removed, reducing the chance of the cancer coming back. A…

This early-stage trial tests a new drug called KUP-101A in 21 people with advanced skin cancers (like melanoma or Merkel cell carcinoma) that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Researchers will also look at …

This early-phase study tests a new drug called 177Lu-RAD204, which combines a targeting antibody with a radioactive particle to seek out and attack cancer cells. The trial involves 30 adults with advanced solid tumors like lung, breast, or skin cancer that have not responded to o…

This study tests two or three drugs (defactinib, avutometinib, and possibly encorafenib) in people with advanced melanoma that has spread to the brain. The goal is to see if these combinations can shrink brain tumors and are safe. About 33 adults whose melanoma worsened after imm…

This early-stage trial tests a new treatment combining two experimental therapies (IMA203 and mRNA-4203) for people with advanced melanoma or synovial sarcoma that has spread or can't be removed. The main goal is to check safety and find the best dose. About 15 participants will …

This early-stage study tests a new drug called MBS8(1V270) in about 106 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the best dose. Researchers will also look for early signs that the drug shrinks tumo…

This study tests a new drug called IDE196 in people with certain cancers that have specific gene mutations (GNAQ/11 or PRKC fusions), including metastatic uveal melanoma and colorectal cancer. The trial has two phases: first to find safe doses, then to see if the drug shrinks tum…

This study tests a new drug called AU-007 in people with advanced solid tumors (like melanoma or lung cancer) that cannot be removed by surgery or have spread. The drug is designed to help the immune system fight cancer more effectively. About 159 participants will receive AU-007…

This study tests whether EMLA numbing cream can reduce pain from Technetium 99 injections used in lymphoscintigraphy, a standard mapping procedure for skin cancers like melanoma. About 100 adults with skin cancer will receive either EMLA cream or a placebo before the injection. R…

This study looks at whether working outdoors in the sun increases the risk of melanoma, a type of skin cancer. Researchers will interview 300 people in Modena, Italy—some with melanoma and some without—about their job history and sun habits. The goal is to better understand the l…

This study looks at how often a specific gene change (BAP1 mutation) occurs in people with certain cancers like eye melanoma, skin melanoma, kidney cancer, and others. Researchers will study 500 patients and their family members to understand cancer patterns and risk factors. The…

This study looks at how lifestyle factors like diet, exercise, mental health, and social support are linked to quality of life and outcomes in people with melanoma. Researchers will survey up to 5,000 participants to gather information. The goal is to use these findings to design…

This study follows 300 adults with stage IIB to IV melanoma who are receiving immune checkpoint inhibitors. Researchers will track 53 different symptoms over time to identify which are most common, severe, and distressing. The goal is to find risk factors linked to worse symptoms…